Background
Methods
Translation of the QLQ-BN20
Validation of the Persian version of the QLQ-BN20
Data collection
Statistical analysis
Results
Total | |
---|---|
Age (years) >Mean (SD)
| 42.5 (16.1) |
Sex
| |
Male | 103 (53.0%) |
Female | 91 (47.0%) |
Educational status
| |
Illiterate | 35 (18.0%) |
Primary school | 33 (17.0%) |
Middle school | 36 (18.6%) |
Secondary school | 48 (24.8%) |
College | 42 (21.6%) |
Marital status
| |
Single | 43 (22.2%) |
Married | 128 (65.9%) |
Widowed/divorced | 23 (11.9%) |
KPS
| |
≤80 | 102 (52.5%) |
>80 | 92 (47.5%) |
MMSE
| |
Mean (SD) | 23.89(5.3) |
Median | 26.00 |
Range | 8-30 |
Type of surgery
| |
Biopsy only | 40 (20.6%) |
Partial resection | 96 (49.5%) |
Total resection | 58 (29.9%) |
Type of adjuvant therapy
| |
CT | 75(38.7%) |
RT | 62 (32%) |
CT + RT | 57 (29.3%) |
Tumor type
| |
Astrocytoma | 72(37.1%) |
Atypical Meningioma* | 46(23.7%) |
Oligodendroglioma | 53(27.3%) |
Others | 23(11.9%) |
Number of forms | Mean (SD) | Floor N (%) | Ceiling (%) | Cronbach’s alpha | Normality (Kolmogoroff-Smirnoff-Test) | ||
---|---|---|---|---|---|---|---|
BFU (future uncertainty) | Baseline | 194 | 39.9 (24.9) | 8 (4.1%) | 3 (1.5%) | 0.80 | 0.14 |
Follow-up | 187 | 36.8 (24.5) | 10 (5.3%) | 3 (1.6%) | 0.74 | 0.24 | |
BVD (visual disorder) | Baseline | 194 | 27.9 (26.9) | 17 (8.7%) | 5 (2.6%) | 0.74 | 0.16 |
Follow-up | 187 | 25.8 (25.9) | 14 (7.4%) | 4 (2.1%) | 0.80 | 0.15 | |
BMD (motor dysfunction) | Baseline | 194 | 29.0 (28.9) | 28 (14.4%) | 6 (3.1%) | 0.80 | 0.46 |
Follow-up | 186 | 28.6 (29.6) | 23 (12.3%) | 3 (1.6%) | 0.82 | 0.18 | |
BCD (communication deficit) | Baseline | 194 | 23.7 (27.2) | 18 (9.2%) | 3 (1.5%) | 0.89 | 0.21 |
BHA (headaches) | Follow-up | 187 | 20.9 (25.0) | 14 (7.5%) | 1 (0.5%) | 0.89 | 0.22 |
Baseline | 192 | 46.9 (33.9) | 25 (13.0%) | 24 (12.5%) | - | 0.19 | |
Follow-up | 187 | 43.6 (35.1) | 21 (11.2%) | 18 (9.6%) | - | 0.15 | |
BSE (seizures) | Baseline | 194 | 10.0 (21.6) | 99 (51.5%) | 7 (3.6%) | - | 0.13 |
Follow-up | 186 | 7.7 (20.0) | 95 (51.0%) | 1 (0.5%) | - | 0.11 | |
BDR (drowsiness) | Baseline | 192 | 32.2 (31.7) | 28 (14.6%) | 11 (5.7%) | - | 0.6 |
Follow-up | 185 | 31.2 (32.0) | 19 (10.3%) | 8 (4.3%) | - | 0.5 | |
BHL (hair loss) | Baseline | 194 | 23.8 (32.5) | 41 (21.1%) | 9 (4.6%) | - | 0.28 |
Follow-up | 187 | 25.9 (44.4) | 38 (20.3%) | 10 (5.3%) | - | 0.06 | |
BIS (itchy skin) | Baseline | 193 | 14.0 (25.8) | 54 (28.0%) | 5 (2.6%) | - | 0.20 |
Follow-up | 186 | 17.8 (27.5) | 46 (24.7%) | 6 (3.2%) | - | 0.32 | |
BWL (weakness of legs) | Baseline | 190 | 28.4 (33.9) | 23 (12.1%) | 14 (7.4%) | - | 0.36 |
BBC (bladder control) | Follow-up | 187 | 28.3 (34.1) | 21 (11.2%) | 12 (6.4%) | - | 0.29 |
Baseline | 194 | 15.1 (25.8) | 67 (34.5%) | 4 (2.0%) | - | 0.20 | |
Follow-up | 186 | 15.2 (30.3) | 58 (31.2%) | 6 (3.2%) | - | 0.30 |
BFU | BVD | BMD | BCD | |
---|---|---|---|---|
BFU (future uncertainty)
| ||||
uncertain about the future |
0.75
| 0.15 | 0.04 | 0.19 |
setbacks in condition |
0.62
| 0.06 | 0.10 | 0.28 |
disruption of family life |
0.78
| 0.23 | 0.10 | 0.17 |
future worsen |
0.67
| 0.21 | 0.18 | 0.04 |
BVD (visual disorder)
| ||||
double vision | 0.14 |
0.67
| 0.11 | 0.18 |
vision blurred | 0.08 |
0.86
| 0.02 | 0.07 |
difficulty reading | 0.16 |
0.83
| 0.10 | 0.05 |
BMD (motor dysfunction)
| ||||
weakness on one side of body | 0.10 | 0.25 |
0.79
| 0.15 |
trouble with coordination | 0.01 | 0.12 |
0.80
| 0.19 |
feel unsteady on your feet | 0.18 | 0.12 |
0.86
| 0.18 |
BCD (communication deficit)
| ||||
Trouble finding the right words to express yourself | 0.14 | 0.21 | 0.11 |
0.88
|
Difficulty speaking | 0.13 | 0.13 | 0.12 |
0.88
|
Trouble communicating thoughts | 0.09 | 0.23 | 0.13 |
0.87
|
KPS | Effect size | MMSE** | Effect size | ||||
---|---|---|---|---|---|---|---|
>80 | ≤80 | <27 | ≥27 | ||||
Baseline | N = 53, | N = 141, | N = 91 | N = 103 | |||
Follow-up | N = 41 | N = 153 | |||||
BFU (future uncertainty) | Baseline*‡ | 42.7 (22.2) | 33.5 (24.7) | 0.38 | 33.9 (24.4) | 27.2 (23.4) | 0.28 |
Follow-up * | 37.0 (15.1) | 25.6 (24.5) | 0.50 | - | - | - | |
BVD (visual disorder) | Baseline *‡ | 38.3 (30.1) | 27.0 (27.3) | 0.40 | 28.1 (29.4) | 21.8 (22.8) | 0.24 |
Follow-up * | 33.3 (27.8) | 23.7 (26.1) | 0.36 | - | - | ||
BMD (motor dysfunction) | Baseline*‡ | 68.2 (31.8) | 24.6 (26.3) | 1.56 | 33.7 (30.2) | 16.5 (22.5) | 0.65 |
Follow-up * | 63.9 (29.1) | 22.4 (27.0) | 1.5 | - | - | ||
BCD (communication deficit) | Baseline *‡ | 44.9 (31.9) | 20.3 (26.5) | 0.88 | 26.1 (28.3) | 14.1 (21.8) | 0.48 |
Follow-up* | 45.0 (33.4) | 17.0 (22.6) | 1.11 | - | - | ||
BHA (headaches) | Baseline *‡ | 50.0 (36.0) | 44.3 (32.2) | 0.17 | 47.8 (28.6) | 34.8 (34.4) | 0.41 |
Follow-up * | 63.3 (36.7) | 42.5 (35.1) | 0.59 | - | - | ||
BSE (seizures) | Baseline *‡ | 15.1 (22.9) | 11.0 (23.3) | 0.18 | 14.3 (25.5) | 5.7 (15.6) | 0.41 |
Follow-up * | 14.8 (24.2) | 8.5 (21.2) | 0.29 | - | - | ||
BDR (drowsiness) | Baseline *‡ | 57.6 (30.1) | 28.3 (31.2) | 0.95 | 34.7 (33.3) | 22.3 (25.0) | 0.42 |
Follow-up * | 66.7 (27.2) | 26.6 (30.5) | 1.34 | - | - | ||
BHL (hair loss) | Baseline*‡ | 33.3 (35.1) | 22.1 (32.2) | 0.34 | 23.4 (32.8) | 16.8 (33.5) | 0.20 |
Follow-up* | 63.3 (36.7) | 42.5 (35.1) | 0.59 | - | - | ||
BIS (itchy skin) | Baseline*‡ | 33.3 (35.1) | 13.2 (24.7) | 0.72 | 19.2 (30.4) | 9.2 (17.6) | 0.41 |
Follow-up* | 40.0 (37.8) | 16.5 (26.5) | 0.80 | - | - | ||
BBC (bladder control) | Baseline*‡ | 45.4 (37.3) | 12.8 (24.2) | 1.15 | 19.0 (27.3) | 9.2 (23.4) | 0.39 |
Follow-up* | 50.0 (42.3) | 12.9 (28.2) | 0.97 | - | - |
KSP | ||||
---|---|---|---|---|
Worsening | Stable | Improved | P value (ANCOVA) | |
N = 59 | N = 49 | N = 79 | ||
Mean (SD) | Mean (SD) | Mean (SD) | ||
Headaches * | 12.4 (29.2) | 1.2 (35.4) | -10.0 (32.6) | 0.04 |
Motor dysfunction* | 6.1 (18.8) | 0.1 (18.2) | -4.3 (15.4) | 0.01 |
Drowsiness | 5.5 (23.2) | 2.4 (27.3) | 1.7 (24.3) | 0.38 |
Weakness of legs*† | 15.2 (28.4) | -1.3 (20.2) | -12.1 (19.3) | <0.01 |
Visual disorder | 5.4 (16.1) | 2.7 (25.4) | 1.6 (22.3) | 0.64 |
Bladder control*† | 9.6 (18.8) | -0.7 (28.9) | -6.6 (26.3) | 0.01 |
Seizures | 5.3 (19.8) | 3.2 (21.8) | 2.7 (17.6) | 0.72 |
Hair loss | 12.4 (29.2) | -4.5 (50.4) | -15.2 (45.4) | 0.08 |
Itchy skin* | 6.5 (20.8) | 0.4 (26.4) | -3.8 (24.8) | 0.02 |